228 related articles for article (PubMed ID: 15180106)
1. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses.
Melegaro A; Edmunds WJ
Eur J Epidemiol; 2004; 19(4):353-63. PubMed ID: 15180106
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis.
Falkenhorst G; Remschmidt C; Harder T; Hummers-Pradier E; Wichmann O; Bogdan C
PLoS One; 2017; 12(1):e0169368. PubMed ID: 28061505
[TBL] [Abstract][Full Text] [Related]
3. The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old--Taiwan's PPV vaccination program.
Tsai YH; Hsieh MJ; Chang CJ; Wen YW; Hu HC; Chao YN; Huang YC; Yang CT; Huang CC
Vaccine; 2015 Jun; 33(25):2897-902. PubMed ID: 25936662
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: A systematic review and meta-analysis of randomized trials.
Diao WQ; Shen N; Yu PX; Liu BB; He B
Vaccine; 2016 Mar; 34(13):1496-1503. PubMed ID: 26899376
[TBL] [Abstract][Full Text] [Related]
5. Advances in pneumococcal vaccines: what are the advantages for the elderly?
Vila-Córcoles A
Drugs Aging; 2007; 24(10):791-800. PubMed ID: 17896829
[TBL] [Abstract][Full Text] [Related]
6. Vaccines for preventing pneumococcal infection in adults.
Moberley SA; Holden J; Tatham DP; Andrews RM
Cochrane Database Syst Rev; 2008 Jan; (1):CD000422. PubMed ID: 18253977
[TBL] [Abstract][Full Text] [Related]
7. Vaccines for preventing pneumococcal infection in adults.
Dear K; Holden J; Andrews R; Tatham D
Cochrane Database Syst Rev; 2003; (4):CD000422. PubMed ID: 14583920
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older.
Vila-Corcoles A; Ochoa-Gondar O; Guzmán JA; Rodriguez-Blanco T; Salsench E; Fuentes CM;
BMC Infect Dis; 2010 Mar; 10():73. PubMed ID: 20298596
[TBL] [Abstract][Full Text] [Related]
9. 23-valent pneumococcal polysaccharide vaccine (PPV23) for the prevention of invasive pneumococcal diseases (IPDs) in the elderly: is it really effective?
Cadeddu C; De Waure C; Gualano MR; Di Nardo F; Ricciardi W
J Prev Med Hyg; 2012 Jun; 53(2):101-3. PubMed ID: 23240169
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with pneumococcal vaccination among an urban elderly population in China.
Liu S; Xu E; Liu Y; Xu Y; Wang J; Du J; Zhang X; Che X; Gu W
Hum Vaccin Immunother; 2014; 10(10):2994-9. PubMed ID: 25483646
[TBL] [Abstract][Full Text] [Related]
11. Vaccines for preventing pneumococcal infection in adults.
Moberley S; Holden J; Tatham DP; Andrews RM
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD000422. PubMed ID: 23440780
[TBL] [Abstract][Full Text] [Related]
12. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of age.
Lucero MG; Dulalia VE; Parreno RN; Lim-Quianzon DM; Nohynek H; Makela H; Williams G
Cochrane Database Syst Rev; 2004 Oct; (4):CD004977. PubMed ID: 15495133
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials.
Fine MJ; Smith MA; Carson CA; Meffe F; Sankey SS; Weissfeld LA; Detsky AS; Kapoor WN
Arch Intern Med; 1994 Dec 12-26; 154(23):2666-77. PubMed ID: 7993150
[TBL] [Abstract][Full Text] [Related]
14. [Is polysaccharide pneumococcal vaccine effective in adults?].
Møller K; Kronborg G; Dirksen A
Ugeskr Laeger; 2001 Oct; 163(44):6112-7. PubMed ID: 11715153
[TBL] [Abstract][Full Text] [Related]
15. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.
Vila-Córcoles A; Ochoa-Gondar O; Hospital I; Ansa X; Vilanova A; Rodríguez T; Llor C;
Clin Infect Dis; 2006 Oct; 43(7):860-8. PubMed ID: 16941367
[TBL] [Abstract][Full Text] [Related]
16. The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: A systematic review and meta-analysis.
Kraicer-Melamed H; O'Donnell S; Quach C
Vaccine; 2016 Mar; 34(13):1540-1550. PubMed ID: 26899372
[TBL] [Abstract][Full Text] [Related]
17. Post-hoc analysis of a randomized controlled trial: Diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly.
Huijts SM; van Werkhoven CH; Bolkenbaas M; Grobbee DE; Bonten MJM
Vaccine; 2017 Aug; 35(34):4444-4449. PubMed ID: 28410813
[TBL] [Abstract][Full Text] [Related]
18. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales.
Andrews NJ; Waight PA; George RC; Slack MP; Miller E
Vaccine; 2012 Nov; 30(48):6802-8. PubMed ID: 23000122
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials.
Cornu C; Yzèbe D; Léophonte P; Gaillat J; Boissel JP; Cucherat M
Vaccine; 2001 Sep; 19(32):4780-90. PubMed ID: 11535330
[TBL] [Abstract][Full Text] [Related]
20. The 23-valent pneumococcal polysaccharide vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales.
Melegaro A; Edmunds WJ
Eur J Epidemiol; 2004; 19(4):365-75. PubMed ID: 15180107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
